bioAffinity Technologies advances CyPath Lung for post-treatment surveillance
bioAffinity Technologies said it is advancing CyPath Lung as a noninvasive surveillance option for lung cancer patients after curative-intent treatment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.